These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15936474)

  • 1. [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
    Masmoudi K; Gras-Champel V; Lemaire-Hurtel AS; Masson H; Munier A; Geslin JM; Andréjak M
    Rev Med Interne; 2005 Jun; 26(6):453-7. PubMed ID: 15936474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases].
    Masmoudi K; Decocq G; Chetaille E; Rosa A; Mizon JP; Andréjak M
    Therapie; 1995; 50(5):451-4. PubMed ID: 8571284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of veralipride.
    De Leo V; Morgante G; Musacchio MC; Faldini E; Delia A; Petraglia F
    Expert Opin Drug Saf; 2006 Sep; 5(5):695-701. PubMed ID: 16907659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson syndrome induced by veralipride].
    Franchignoni FP; Tesio L
    Minerva Ginecol; 1995 Jun; 47(6):277-9. PubMed ID: 7478098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
    Melis GB; Gambacciani M; Cagnacci A; Paoletti AM; Mais V; Fioretti P
    Obstet Gynecol; 1988 Nov; 72(5):688-92. PubMed ID: 3140150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
    Teive HA; Sa DS
    Arq Neuropsiquiatr; 2001 Mar; 59(1):123-4. PubMed ID: 11299446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veralipride-induced tardive dystonia in a patient with bipolar psychosis.
    Gabellini AS; Pezzoli A; De Massis P; Sacquegna T
    Ital J Neurol Sci; 1992 Oct; 13(7):621-3. PubMed ID: 1428799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women.
    Verbeke K; Dhont M; Vandekerckhove D
    Maturitas; 1988 Oct; 10(3):225-30. PubMed ID: 3185294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Veralipride and menopause].
    Laffargue F; Viala JL; Durand G
    Sem Hop; 1983 Sep; 59(29-30):2127-30. PubMed ID: 6312585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases.
    Masmoudi K; Masson H; Gras V; Andréjak M
    Fundam Clin Pharmacol; 2012 Apr; 26(2):198-203. PubMed ID: 22044594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes.
    Carretti N; Florio P; Reis FM; Comai S; Bertazzo A; Petraglia F
    Climacteric; 2010 Apr; 13(2):141-6. PubMed ID: 20082603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma.
    Montemurro D; Rossi GP
    J Endocrinol Invest; 2006; 29(7):650-2. PubMed ID: 16957415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.
    Musco S; Ruekert L; Myers J; Anderson D; Welling M; Cunningham EA
    J Clin Psychopharmacol; 2019; 39(4):336-343. PubMed ID: 31205194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Setting the record straight: The nosology of tardive syndromes.
    Truong DD; Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():146-150. PubMed ID: 30528171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-hormonal therapy for menopausal disorders: results of a multicentric double-blind trial (author's transl)].
    Linquette M; Rivière J; Vague J
    Sem Hop; 1980 Oct; 56(37-38):1445-8. PubMed ID: 6254159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of the action of a new molecule, veralipride, on menopausal psychofunctional disorders (author's transl)].
    Delanian L
    Sem Hop; 1980 Oct; 56(37-38):1468-70. PubMed ID: 6254163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride].
    Wesel S; Bosuma WB
    Sem Hop; 1983 Mar; 59(9):596-9. PubMed ID: 6304907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Veralipride in the treatment of hot flushes in the menopause].
    Pasetto N; Piccione E; Baschieri L
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):163-5. PubMed ID: 3922035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of menopausal hot flushes with a nonhormonal medication, veralipride].
    Marzolf G; Eberst B; Aerts A; Lecornu C; Mark J; Gandar R
    Sem Hop; 1982 Nov; 58(41):2382-4. PubMed ID: 6297023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.